Altria Group, Inc. (MO) 2024 10-K Earnings Analysis
Altria Group, Inc.2024 Earnings Analysis
75/100
Altria Group, Inc.'s FY2024 10-K for the period ended December 31, 2024 is easiest to read through $24.0B of revenue, $11.3B of net income, and $8.61B of free cash flow. Per SEC and company filings, aB InBev Equity Investment, FDA Regulatory Risk, and ESG Mandates remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Gross margin was 59.8% and operating margin was 46.8%, with AB InBev Equity Investment still doing the economic work, so FY2024 does not look like a year bought with weak pricing or loose cost control. Per SEC and company filings, the next test is whether FDA Regulatory Risk and ESG Mandates stay manageable without compromising returns.
Filing analysis
Altria Group, Inc. 2024 10-K Analysis
This page reads Altria Group, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 75/100, or grade C.
MO Earnings Quality
The earnings-quality module scores 80/100, with Gross Margin: 59.8%, Operating Margin: 46.8%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
MO Economic Moat Analysis
The moat-strength module scores 80/100, with Marlboro Franchise: 50%+ category share, Pricing Power: Annual price escalators. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
MO Free Cash Flow vs Net Income
CF/Net Income: 0.78x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
MO Key Risks from the Annual Report
The risk module scores 60/100, with Cigarette Volume Decline: Multi-year secular, FDA Regulatory Risk: Menthol/PMTA/PMP. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is MO a High Quality Earnings Stock?
Based on this 2024 filing, MO passes the first screen for high-quality earnings: the overall grade is C, and the earnings-quality score is 80/100. This is a research screen, not investment advice.
Read the report first
Understand Altria Group, Inc. first, then decide if it belongs on your watchlist
The MO score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep MO with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the MO report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross Margin is worth reading alongside the rest of the file because gross Margin is worth reading alongside the rest of the file because gross margin of 59.8% reflects the disclosed cigarette-franchise economics — branded Marlboro pricing-power plus excise tax pass through structure.
On operating margin, the useful point is that on operating margin, the useful point is that the 46.8% operating margin reflects the disclosed cigarette-segment economics — high incremental-margin pricing-realization on declining-volume base.
CF / Net Income matters here because CF / Net Income matters here because OCF of $8.75B is 0.78x net income of $11.26B — reflects the AB InBev investment-related non-cash mark to market gains in NI per the equity method investment disclosure.
FY2024 10-K shows $11.3B of net income on $24.0B of revenue, but the cleaner read is the $8.75B of operating cash flow that turned into $8.61B of free cash flow. Per SEC and company filings, aB InBev Equity Investment and FDA Regulatory Risk help explain why the margin profile stayed where it did instead of collapsing with every demand wobble. Operating margin landed at 46.8%, while AB InBev Equity Investment absorbed capex running at 0.6% of revenue. Cash conversion around AB InBev Equity Investment is the part of the file to keep watching, because the accounting result is stronger than the cash result right now.
Moat Strength
Marlboro Franchise matters because marlboro Franchise matters because marlboro holds 50%+ of the US cigarette category share as described in the market-share communications — a multi-decade competitive position.
What pricing power really tells you is that what pricing power really tells you is that altria has executed multi-year annual cigarette price increases as described in the pricing-realization communications — net pricing realization principally offsets volume declines per the segment-trajectory.
The practical value of smokeless pivot execution is that the practical value of smokeless pivot execution is that altria's smokeless-pivot strategy (NJOY-acquired e-vapor + on!-oral nicotine pouch development) has had mixed early execution as described in the segment-revenue trajectory.
Per SEC and company filings, the competitive position starts with AB InBev Equity Investment and FDA Regulatory Risk, not with a vague appeal to scale. ESG Mandates and JUUL / NJOY Writedowns matter because they deepen switching friction, expand installed-base economics, or widen route to market reach. FY2024 ROE was -503.3%, but the more important check is that AB InBev Equity Investment still turns operating advantages into cash and margin support. That does not make the business immune; it means a competitor still has to overcome AB InBev Equity Investment and a functioning operating system rather than just a familiar name.
Capital Allocation
Free Cash Flow is relevant because free Cash Flow is relevant because FCF of $8.61B (OCF $8.75B minus capex $142M) supports the disclosed dividend and share-repurchase program.
On high-payout dividend, the file suggests that on high-payout dividend, the file suggests that altria targets approximately 80% earnings-payout ratio as described in the capital-allocation framework — among the highest dividend yields in the S&P 500 per public market-data.
JUUL / NJOY Writedowns tells you that JUUL / NJOY Writedowns tells you that the JUUL investment was largely written down as described in the historical impairment communications — a significant capital-allocation misstep historically.
$8.61B of free cash flow is the starting point for the capital-allocation discussion, because it defines how much room management actually had after funding AB InBev Equity Investment and the broader business. Capex intensity is light at 0.6% of revenue, so the real allocation decision is what management does with the cash left after maintaining AB InBev Equity Investment and the platform. The balance sheet is intentionally equity-light after years of repurchases, so continued cash generation matters more than the accounting equity line. The capital-return file is split between the dividend and share repurchases, with room for both as long as cash generation stays near the current level.
Key Risks
Cigarette Volume Decline belongs on the watch list because cigarette Volume Decline belongs on the watch list because US cigarette industry-volume declines persist as described in the multi-year volume-trajectory — pricing-realization has principally offset volume declines but the trajectory remains a structural risk.
Per SEC and company filings, the point of fda regulatory risk is that the point of fda regulatory risk is that PMTA reviews as described in the regulatory pathway) creates ongoing regulatory risk.
ESG Mandates matters as a risk because ESG Mandates matters as a risk because tobacco-industry exclusion from many ESG and passive fund mandates creates structural shareholder base headwinds per public market communications.
The risk section is better read through FDA Regulatory Risk and ESG Mandates than as one binary red flag. Per SEC and company filings, fDA Regulatory Risk can travel into margins and cash conversion faster than the headline score suggests once ESG Mandates starts building. Goodwill is 19.7% of assets, so portfolio execution around AB InBev Equity Investment and acquisition discipline remain part of the risk discussion. Per SEC and company filings, the next test is whether FDA Regulatory Risk and ESG Mandates stay manageable without compromising returns.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.